Support CleanTechnica’s work through a Substack subscription or on Stripe. On the Tesla conference call for shareholders this week, Elon Musk sounded like “old,” more normal Elon for much of it. He was mostly focused on certain tech issues at Tesla. However, he also made some wild, fantastical, unrealistic claims. (Some would claim that is… Continue reading Clean Technica: The Stupidest Thing Elon Musk Said This Week004223
Tag: Tesla
Tesla driver avoids plane crash caught on video, fans falsely credit self-driving
Tesla fans celebrated what they claim was a Tesla vehicle on Full Self-Driving (FSD) that avoided a literal plane crashing into the road. However, the driver confirmed that the Tesla vehicle was not in Full Self-Driving mode. Tesla fans often complain that some drivers using Autopilot and Full Self-Driving (FSD), Tesla’s advanced driver assistance systems… Continue reading Tesla driver avoids plane crash caught on video, fans falsely credit self-driving
TechCrunch Mobility: The ‘robot army’ argument
Welcome back to TechCrunch Mobility — your central hub for news and insights on the future of transportation. To get this in your inbox, sign up here for free — just click TechCrunch Mobility! I am sure you are waiting to learn the results of last week’s poll. (Reminder: Sign up for the Mobility newsletter… Continue reading TechCrunch Mobility: The ‘robot army’ argument
Protective film: Ghost sign on the Cybertruck
Lettering appeared on Cybertrucks that was only visible when it was wet. What initially looked like vandalism turned out to be a manufacturing defect. (Tesla Cybertruck, Electric car) Go to Source
Geely targets 100,000 UK sales in push to take on Tesla and BYD
Save 40% on Standard Digital was $540 now $319 for your first year Savings based on monthly annualised price, offer ends 29th October. Go to Source
Ex–Stellantis CEO says Tesla could exit the car industry and may not exist in 10 years: ‘Tesla’s stock market value loss will be colossal’
Car executives once saw Tesla as their industry’s biggest disrupter. But now, at least one former automotive CEO says the company may pull out of the car business, and could even cease to exist within 10 years. Carlos Tavares, who resigned from the top job at Jeep manufacturer Stellantis late last year, said Elon Musk’s… Continue reading Ex–Stellantis CEO says Tesla could exit the car industry and may not exist in 10 years: ‘Tesla’s stock market value loss will be colossal’
Clean Technica: AI Bubbles & Robot Armies004222
Support CleanTechnica’s work through a Substack subscription or on Stripe. It seems that AI and robots are all the rage these days. The future is all about AI and robots. I keep getting fed stories about these, some extremely optimistic, some extremely pessimistic. The following are a few big stories and comments from recent weeks.… Continue reading Clean Technica: AI Bubbles & Robot Armies004222
Clean Technica: “We Don’t Need No Stinking New Models!” —Tesla004221
Support CleanTechnica’s work through a Substack subscription or on Stripe. Riffing on a unique story or two by Zachary Shahan yesterday, Reuters this morning has a report with this cheery headline: “Tesla gambles that introducing new models no longer matters.” CleanTechnica readers, being unusually astute, are well aware that Tesla has not introduced a new… Continue reading Clean Technica: “We Don’t Need No Stinking New Models!” —Tesla004221
Clean Technica: Shocking Differences Between Tesla & 20 Top Automakers — Market Cap vs. Revenue & EBIT004220
Support CleanTechnica’s work through a Substack subscription or on Stripe. I ran across some shocking comparisons tonight. Apparently, someone shared the other day that Tesla’s market cap is higher than the combined market caps of the next 20 automakers. We’ve written about this kind of thing in the past, but it has been a while… Continue reading Clean Technica: Shocking Differences Between Tesla & 20 Top Automakers — Market Cap vs. Revenue & EBIT004220
Published in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies
Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score , which is based on 11 key systemic disease domains, at Week 24 versus placebo Critical patient-reported SjD symptoms including dryness, pain and fatigue trended towards greater improvement in the… Continue reading Published in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies